RedHill Biopharma Reports 2024 Financials & Highlights
Ticker: RDHL · Form: 6-K · Filed: Apr 10, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operational-highlights, foreign-private-issuer
Related Tickers: RHBP
TL;DR
RHBP dropped its 2024 year-end financials - check the press release for deets.
AI Summary
RedHill Biopharma Ltd. announced its full-year 2024 financial results and operational highlights via a press release filed on April 10, 2025. The company is a foreign private issuer and files annual reports on Form 20-F.
Why It Matters
This filing provides investors with the latest financial performance and key operational updates for RedHill Biopharma, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, RedHill Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- 2024 (date) — Reporting period for financial results
- April 10, 2025 (date) — Filing date of the 6-K
- Form 20-F (document) — Annual report form
- Form 6-K (document) — Current report form
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing incorporates by reference a press release announcing RedHill Biopharma's full-year 2024 financial results and operational highlights.
What is RedHill Biopharma's principal executive office address?
RedHill Biopharma's principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Does RedHill Biopharma file annual reports on Form 20-F or Form 40-F?
RedHill Biopharma files its annual reports on Form 20-F.
When was the press release regarding the 2024 financial results filed?
The press release was filed on April 10, 2025, as part of this Form 6-K.
What are the SEC file number and film number for this filing?
The SEC file number is 001-35773 and the film number is 25826513.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 10, 2025 regarding RedHill Biopharma Ltd. (RDHL).